Bayer drug-device combos gain 'infectious disease' status
This article was originally published in Scrip
Executive Summary
Two of Bayer HealthCare's investigational agents, amikacin inhale (BAY 41-6551) and ciprofloxacin dry powder for inhalation (DPI), were designated as qualified infectious disease products (QIDPs) by the FDA, the company revealed on 24 November.